EGFR and non-small cell lung carcinoma: A phase I study investigated the combination of MK-2206 and gefitinib in NSCLC patients who failed prior chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (NCT01147211) (Lin et al., 2010).